Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
PURPOSE: The efficacy and safety of combining bevacizumab (7.5 and 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2) -negative, locally recurrent or metastatic breast cancer (MBC) was investigated in a three-arm, placebo-controlled, phase III trial. -...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 10 2010
|
| In: |
Journal of clinical oncology
Year: 2010, Jahrgang: 28, Heft: 20, Pages: 3239-3247 |
| ISSN: | 1527-7755 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.2008.21.6457
|
| Verfasserangaben: | David W. Miles, Arlene Chan, Luc Y. Dirix, Javier Cortés, Xavier Pivot, Piotr Tomczak, Thierry Delozier, Joo Hyuk Sohn, Louise Provencher, Fabio Puglisi, Nadia Harbeck, Guenther G. Steger, Andreas Schneeweiss, Andrew M. Wardley, Andreas Chlistalla, and Gilles Romieu |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1843596687 | ||
| 003 | DE-627 | ||
| 005 | 20230710142122.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230426s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2008.21.6457 |2 doi | |
| 035 | |a (DE-627)1843596687 | ||
| 035 | |a (DE-599)KXP1843596687 | ||
| 035 | |a (OCoLC)1389806392 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Miles, David W. |e VerfasserIn |0 (DE-588)1244965286 |0 (DE-627)1776049624 |4 aut | |
| 245 | 1 | 0 | |a Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer |c David W. Miles, Arlene Chan, Luc Y. Dirix, Javier Cortés, Xavier Pivot, Piotr Tomczak, Thierry Delozier, Joo Hyuk Sohn, Louise Provencher, Fabio Puglisi, Nadia Harbeck, Guenther G. Steger, Andreas Schneeweiss, Andrew M. Wardley, Andreas Chlistalla, and Gilles Romieu |
| 264 | 1 | |c July 10 2010 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.04.2023 | ||
| 520 | |a PURPOSE: The efficacy and safety of combining bevacizumab (7.5 and 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2) -negative, locally recurrent or metastatic breast cancer (MBC) was investigated in a three-arm, placebo-controlled, phase III trial. - PATIENTS AND METHODS: Patients (N = 736) were randomly assigned to docetaxel 100 mg/m(2) plus either placebo or bevacizumab 7.5 or 15 mg/kg every 3 weeks. The primary end point was progression-free survival (PFS); secondary end points included best overall response, duration of response, time to treatment failure, overall survival, and safety. - RESULTS: Combination of bevacizumab 15 mg/kg, but not 7.5 mg/kg, with docetaxel showed superior median PFS (mPFS) to placebo plus docetaxel in unstratified analysis (placebo mPFS, 8.2 months; 7.5 mg/kg mPFS, 9.0 months [hazard ratio (HR), 0.86; P = .12]; 15 mg/kg mPFS, 10.1 months [HR, 0.77; P = .006]) and stratified analysis (placebo mPFS, 8.1 months; 7.5 mg/kg mPFS, 9.0 months [HR, 0.80; P = .045]; 15 mg/kg mPFS, 10.0 months [HR, 0.67; P < .001]). Response rates in patients with measurable disease at baseline also increased with bevacizumab 15 mg/kg (46% [placebo] v 55% [7.5 mg/kg; P = .07] and 64% [15 mg/kg; P < .001]). Combination with bevacizumab had limited impact on the known toxicity profile of docetaxel. - CONCLUSION: Combination of bevacizumab with docetaxel did not significantly impact on the safety profile of docetaxel. Bevacizumab 15 mg/kg every 3 weeks significantly increased PFS when combined with docetaxel as first-line therapy for MBC compared with docetaxel plus placebo. | ||
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Aged | |
| 650 | 4 | |a Aged, 80 and over | |
| 650 | 4 | |a Antibodies, Monoclonal | |
| 650 | 4 | |a Antibodies, Monoclonal, Humanized | |
| 650 | 4 | |a Antineoplastic Combined Chemotherapy Protocols | |
| 650 | 4 | |a Bevacizumab | |
| 650 | 4 | |a Breast Neoplasms | |
| 650 | 4 | |a Docetaxel | |
| 650 | 4 | |a Drug Administration Schedule | |
| 650 | 4 | |a ErbB Receptors | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Middle Aged | |
| 650 | 4 | |a Neoplasm Metastasis | |
| 650 | 4 | |a Neoplasm Recurrence, Local | |
| 650 | 4 | |a Placebos | |
| 650 | 4 | |a Taxoids | |
| 700 | 1 | |a Chan, Arlene |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dirix, Luc Y. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cortés, Javier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pivot, Xavier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tomczak, Piotr |e VerfasserIn |4 aut | |
| 700 | 1 | |a Delozier, Thierry |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sohn, Joo Hyuk |e VerfasserIn |4 aut | |
| 700 | 1 | |a Provencher, Louise |e VerfasserIn |4 aut | |
| 700 | 1 | |a Puglisi, Fabio |e VerfasserIn |4 aut | |
| 700 | 1 | |a Harbeck, Nadia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Steger, Guenther G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Wardley, Andrew M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chlistalla, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Romieu, Gilles |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 28(2010), 20, Seite 3239-3247 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer |
| 773 | 1 | 8 | |g volume:28 |g year:2010 |g number:20 |g pages:3239-3247 |g extent:9 |a Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.2008.21.6457 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230426 | ||
| 993 | |a Article | ||
| 994 | |a 2010 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |d 50000 |e 910000PS109972554 |e 910400PS109972554 |e 50000PS109972554 |k 0/910000/ |k 1/910000/910400/ |k 0/50000/ |p 13 | ||
| 999 | |a KXP-PPN1843596687 |e 4314664029 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 26.04.2023"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"July 10 2010","dateIssuedKey":"2010"}],"person":[{"role":"aut","given":"David W.","family":"Miles","display":"Miles, David W."},{"role":"aut","display":"Chan, Arlene","family":"Chan","given":"Arlene"},{"family":"Dirix","given":"Luc Y.","display":"Dirix, Luc Y.","role":"aut"},{"given":"Javier","family":"Cortés","display":"Cortés, Javier","role":"aut"},{"role":"aut","display":"Pivot, Xavier","given":"Xavier","family":"Pivot"},{"role":"aut","given":"Piotr","family":"Tomczak","display":"Tomczak, Piotr"},{"given":"Thierry","family":"Delozier","display":"Delozier, Thierry","role":"aut"},{"given":"Joo Hyuk","family":"Sohn","display":"Sohn, Joo Hyuk","role":"aut"},{"role":"aut","given":"Louise","family":"Provencher","display":"Provencher, Louise"},{"family":"Puglisi","given":"Fabio","display":"Puglisi, Fabio","role":"aut"},{"family":"Harbeck","given":"Nadia","display":"Harbeck, Nadia","role":"aut"},{"role":"aut","display":"Steger, Guenther G.","family":"Steger","given":"Guenther G."},{"family":"Schneeweiss","given":"Andreas","display":"Schneeweiss, Andreas","role":"aut"},{"given":"Andrew M.","family":"Wardley","display":"Wardley, Andrew M.","role":"aut"},{"role":"aut","given":"Andreas","family":"Chlistalla","display":"Chlistalla, Andreas"},{"display":"Romieu, Gilles","family":"Romieu","given":"Gilles","role":"aut"}],"title":[{"title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","title_sort":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer"}],"language":["eng"],"physDesc":[{"extent":"9 S."}],"relHost":[{"recId":"313116962","id":{"eki":["313116962"],"issn":["1527-7755"],"zdb":["2005181-5"]},"disp":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancerJournal of clinical oncology","physDesc":[{"extent":"Online-Ressource"}],"corporate":[{"role":"isb","display":"American Society of Clinical Oncology"}],"part":{"extent":"9","pages":"3239-3247","volume":"28","text":"28(2010), 20, Seite 3239-3247","issue":"20","year":"2010"},"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"language":["eng"],"title":[{"title":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal","title_sort":"Journal of clinical oncology"}],"pubHistory":["1.1983 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedDisp":"1983-","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedKey":"1983"}],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"]}],"name":{"displayForm":["David W. Miles, Arlene Chan, Luc Y. Dirix, Javier Cortés, Xavier Pivot, Piotr Tomczak, Thierry Delozier, Joo Hyuk Sohn, Louise Provencher, Fabio Puglisi, Nadia Harbeck, Guenther G. Steger, Andreas Schneeweiss, Andrew M. Wardley, Andreas Chlistalla, and Gilles Romieu"]},"recId":"1843596687","id":{"eki":["1843596687"],"doi":["10.1200/JCO.2008.21.6457"]}} | ||
| SRT | |a MILESDAVIDPHASEIIIST1020 | ||